14-day Premium Trial Subscription Try For FreeTry Free
-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that UnitedHealthcare, one of the largest commercial health care plans in the United States, covering approximately 13 million lives, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. EYSUVIS now has coverage for approximately 118 million lives, or 70% of all commercial lives.
ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement

Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know

08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals Inc (KALA) shares closed today at 1.0% above its 52 week low of $1.01, giving the company a market cap of $68M. The stock is currently down 13.2% year-to-date, down 86.1% over the past 12 months, and down 94.3% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 4.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 326.0% The company's stock price performance over the past 12 months lags the peer average by 378.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kala Pharmaceuticals Inc Shares Near 52-Week Low - Market Mover

09:26pm, Sunday, 09'th Jan 2022 Kwhen Finance
Kala Pharmaceuticals Inc (KALA) shares closed today at 0.9% above its 52 week low of $1.07, giving the company a market cap of $70M. The stock is currently down 10.7% year-to-date, down 85.8% over the past 12 months, and down 94.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 148.6% The company's stock price performance over the past 12 months lags the peer average by 359.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Kala Pharmaceuticals Inc (KALA) shares closed today at 0.9% above its 52 week low of $1.07, giving the company a market cap of $70M. The stock is currently down 10.7% year-to-date, down 84.7% over the past 12 months, and down 94.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 9.2% lower than its 5-day moving average, 17.6% lower than its 20-day moving average, and 48.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 148.6% The company's stock price performance over the past 12 months lags the peer average by 343.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Kala Pharmaceuticals Inc (KALA) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $78M. The stock is currently down 82.3% year-to-date, down 83.5% over the past 12 months, and down 93.5% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 702.8% The company's stock price performance over the past 12 months lags the peer average by 763.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kala Pharmaceuticals Inc Shares Near 52-Week Low - Market Mover

11:06am, Tuesday, 28'th Dec 2021 Kwhen Finance
Kala Pharmaceuticals Inc (KALA) shares closed today at 0.8% above its 52 week low of $1.22, giving the company a market cap of $80M. The stock is currently down 81.9% year-to-date, down 83.9% over the past 12 months, and down 93.3% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 18.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 751.6% The company's stock price performance over the past 12 months lags the peer average by 611.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awar
Equities analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to post sales of $3.49 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Kala Pharmaceuticals earnings, with estimates ranging from $3.24 million to $4.01 million. Kala Pharmaceuticals posted sales of $2.24 million in the same quarter last year, which []
California State Teachers Retirement System raised its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 11.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,592 shares of the companys stock after acquiring an additional 6,915 shares during the period. California []

Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch

09:11pm, Tuesday, 30'th Nov 2021 PennyStocks
Looking for short squeeze penny stocks? Give these 5 a look. The post Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information |
Looking for short squeeze penny stocks? Give these 5 a look.
Nuveen Asset Management LLC trimmed its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 36.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 181,653 shares of the companys stock after selling 102,986 shares during the quarter. Nuveen Asset Management LLC owned []
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE